Abstract
BackgroundDespite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have